A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...

Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...

In an ongoing clinical trial, researchers are testing whether just one dose of a new gene therapy that might effectively cure human immunodeficiency virus (HIV) infections is safe in humans. According ...

The anonymous success story, dubbed the next Berlin Patient, is the first person to be cured without donated stem cells from someone completely immune to HIV. Reading time 3 minutes Doctors have ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

On Wednesday, Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). ALLIANCE is ...